Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases ...

Scotiabank lowered the firm’s price target on Apellis (APLS) to $30 from $35 and keeps a Sector Perform rating on the shares. The company ...

Baird lowered the firm’s price target on Apellis (APLS) to $55 from $92 and keeps an Outperform rating on the shares. The firm said they reported 3Q24 results, including a sequentially lower Syfovre ...

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2024 financial results and business highlights. “The third ...

Apellis stock toppled Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations. Please watch the video at Investors.com - How To Buy Stocks ...

Overall, Apellis reported total third-quarter revenues of $196.8 million, up 78% year over year. Beyond Syfovre, the company’s paroxysmal nocturnal hemoglobinuria drug Empaveli grew sales 0.4% ...

Tuesday's big news with Apellis Pharmaceuticals (NASDAQ: APLS) wasn't all that favorable to the company. It released its third-quarter results, and the market wasn't all that pleased with the figures.

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...

Apellis' chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data from two ...

Short interest in Apellis Pharmaceuticals Inc (NASDAQ:APLS) increased during the last reporting period, rising from 15.26M to 21.09M. This put 23.91% of the company's publicly available shares short.